So far this year, the RxStrategies team has traveled from San Francisco to Washington D.C.—with many stops in between—to share the latest developments on the 340B drug discount program. Throughout the rest of the year, we will be attending and presenting at conferences in Florida, Alabama, Alaska, Georgia, California and New Orleans. Aug. 21-25 RxStrategies… Read more »
-
-
August 340B Insider
Welcome to the August edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. 340B RECERTIFICATION REMINDER Recertification Deadline September 9 340B Health sent a reminder to Covered Entities (CEs) regarding the Sept. 9 deadline to recertify information in the 340B program database. It is vital to… Read more »
-
RxStrategies, Inc. Names Rhodie Smith National Sales Manager
BOCA RATON, Florida, September 4, 2014-RxStrategies, Inc. is pleased to announce the appointment of Rhodie Smith to National Sales Manager. In this new role, Rhodie joins the RxStrategies’ senior leadership team and is responsible for sales and delivery of customized 340B pharmacy administration and split billing solutions to the growing 340B marketplace. “I am very… Read more »
-
RxS UPDATES: RxStrategies Web Portal Update
In our continuing commitment to provide usable tools and resources, the RxStrategies IT team has updated the web portal to include order status for all replenishment drugs. It is now possible to review all orders placed and the disposition of them in real-time. If you have not yet utilized the web portal and are in… Read more »
-
HRSA UPDATES: Hospital Recertification Required
The annual recertification process is scheduled to begin on Aug. 6 and conclude on Sept. 10, 2014. Hospitals should receive an email containing instructions from HRSA’s Office of Pharmacy Affairs (OPA) around Aug. 1 and will have five (5) weeks to complete the process after it begins on Aug. 6. The purpose of annual recertification is twofold:… Read more »
-
RxStrategies Sponsors 340B PAC Breakfast and Legislative Outreach
As a contributing sponsor of the 340B PAC (and and Advisory Board Member for PAC), RxStrategies hosted former U.S. Rep. Bart Stupak at a breakfast meeting on Tuesday, July 15, 2014, where he spoke out on the need to continue to support the 340B program. He also encouraged all participating entities and organizations to write… Read more »
-
UPDATE FROM 340B COALITION SUMMER CONFERENCE
340B “Mega-Reg” Update The White House Office of Management and Budget (OMB) began its review of a proposed 340B Drug Pricing Program “Mega-Reg” in April. (See: RIN 0906-AB04). This proposed rule change is expected to cover the definition of an eligible patient and establish comprehensive 340B Drug Pricing Program requirements for participating covered entities and manufacturers.… Read more »
-
340B Orphan Drug Rule Invalidated
U.S. District Judge Rudolph Contreras has ruled that HRSA lacks regulatory authority to promulgate regulations expanding access to 340B discounts for so-called Orphan Drugs. Rules that went into effect in October of 2013 implemented provisions of the Affordable Care Act that excluded orphan drugs from 340B pricing. In the rules HRSA interpreted the exception… Read more »
-
Family Planning Re-certification Webinar
RECERTIFICATION: FAMILY PLANNING (3/24/2014) The Office of Pharmacy Affairs (OPA) is required to recertify all participating 340b covered entities annually to ensure 340B database accuracy and promote compliance with 340B program requirements. OPA will hold an informational recertification webinar for Title X Family Planning Grantees on April 2nd, 2014, from 2-3 PM EDT. Conference Number:… Read more »
-
Promising Hepatitis C Treatment’s Cure Rates, Costs Highlighted
The Denver Post (Draper, 3/5) reported that Sovaldi (sofosbuvir) is being seen as a blockbuster medicine after studies show that it cured 90 percent of hepatitis C patients in just 12 weeks. However, a major issue with the therapy is its exorbitant cost: $1,000 a day. Insurers still have not decided about the coverage options,… Read more »